ResearcherChina Pharmaceutical UniversityActive in the last 2 years

Rui Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4719-9921; OpenAlex author ID A5002827288, A5100431254. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xin Gao · 1 shared paper, 2026 · strength 0.33
- Paper Chemically Evolved Integrin α5β1-Targeted Peptide PET Tracers for Orthotopic Pancreatic Ductal Adenocarcinoma Detection. DOI 10.1021/acs.jmedchem.6c00955 ↗
Yang Zhou · 1 shared paper, 2019 · strength 0.09
- Paper Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway. DOI 10.1016/j.redox.2019.101131 ↗
Yunjiang Zhou · 1 shared paper, 2019 · strength 0.09
- Paper Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway. DOI 10.1016/j.redox.2019.101131 ↗
Rong Hu · 1 shared paper, 2019 · strength 0.09
- Paper Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway. DOI 10.1016/j.redox.2019.101131 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.